Literature DB >> 15603253

Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides.

Rosie Z Yu1, Richard S Geary, Arthur A Levin.   

Abstract

The development of antisense therapeutic agents has required the development of a number of novel bioanalytical methods for their quantitation. The success of these methods has enabled characterization of the pharmacokinetic and pharmacokinetic/ pharmacodynamic behavior of antisense agents. Specific quantitative bioanalytical methods addressed in this review include radiotracer methods, high-performance liquid chromatography (HPLC) methods, capillary gel electrophoresis with UV detection or with laser-induced fluorescence detection, matrix-assisted laser-induced desorption/ionization mass spectrometry, HPLC-mass spectrometry, and hybridization-based enzyme-linked immunosorbent assays. The most important bioanalytical techniques have been summarized in view of their general and specific features, the possibilities and extent of their application, and characteristics of operation and limitations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15603253

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  7 in total

1.  A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.

Authors:  Xiaohui Wei; Guowei Dai; Guido Marcucci; Zhongfa Liu; Dale Hoyt; William Blum; Kenneth K Chan
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

Review 2.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Phosphorothioate oligonucleotide quantification by μ-liquid chromatography-mass spectrometry.

Authors:  Robert Erb; Katharina Leithner; Andreas Bernkop-Schnürch; Herbert Oberacher
Journal:  AAPS J       Date:  2012-07-18       Impact factor: 4.009

4.  Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.

Authors:  Richard S Geary; JoAnn D Bradley; Tanya Watanabe; Younggil Kwon; Mark Wedel; Jan J van Lier; André A VanVliet
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.

Authors:  Ryosuke Shimizu; Mikiko Kitade; Takashi Kobayashi; Shin-Ichiro Hori; Ayahisa Watanabe
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-11-07       Impact factor: 2.745

6.  Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.

Authors:  Houda Alachkar; Zhiliang Xie; Guido Marcucci; Kenneth K Chan
Journal:  J Pharm Biomed Anal       Date:  2012-08-19       Impact factor: 3.935

7.  A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.

Authors:  Michael Monine; Daniel Norris; Yanfeng Wang; Ivan Nestorov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-15       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.